Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2

Abstract

The new wave of COVID-19 in Europe and the emergence of a new variant of concern called Omicron, first detected in southern African countries then subsequently in Europe, Asia and America, demands once again rapid and equitable access to vaccines especially in low-income countries. In stark contrast with a large number of published papers related to the vaccines BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/ NIAID), and (ChAdOx1-S Astrazeneca/ University of Oxford), very few reports have been published referring to the Sputnik-V vaccine (Gamaleya National Center of Epidemiology and Microbiology). Sputnik-V is being used in more than 70 countries, mainly in South America, Africa and Asia, but has not been yet approved for emergency use by the World Health Organization. In The Lancet Regional Health−Americas, Chahla RE and colleagues report a long-term analysis of the antibody response in 602 health workers from Argentina vaccinated by Sputnik V between December 2020 and July 2021. Confirming previous results published in phase I/II studies,1 the authors report seroconversion levels of 97% at 7 days after the application of the second dose. Follow-up of vaccinated individuals showed that the serum levels of IgG anti-RBD antibodies remain detectable in 94% of individuals at 90 days after vaccination, decreasing this percentage to 31% at 180 days after vaccination.